Spearheading Affordable Access & Driving Value with Innovative Payment Models & Reimbursement Solutions to Advance Coverage of Transformative Cell & Gene Therapies to Patients in Need
The cell and gene therapy sector is accelerating faster than the systems designed to pay for it. With over 39 FDA‑approved therapies and 80+ expected by 2032, more companies are reaching commercialization…but many are still struggling to achieve real patient access.
Recent examples have made this clear. From therapies facing low uptake post‑approval to Regeneron offering its gene therapy at no cost due to reimbursement challenges, success now depends on getting pricing, evidence, and access strategy right early.
That’s why the 3rd Cell & Gene Therapy Pricing & Reimbursement Summit exists.
Returning to Washington DC, this is the only meeting bringing together biopharma, payers, policymakers, and providers to focus on how to align evidence, value communication, and contracting strategy before and beyond launch.
Through case studies from recently approved companies and direct payer insight, you’ll leave with practical strategies to secure coverage, avoid launch pitfalls, and drive real patient uptake.
Join the stakeholders shaping the future of CGT access in 2026 and beyond.
Great conference on an extremely important topic. Presentations were very good and thought-provoking.
Head of Market Access, CSL, 2025 Speaker
Great line up of speakers, very relevant topics and actionable insights. Also, appreciated networking opportunities.
Vice President, Business Analytics, Neurogene, 2024 Attendee
It is critical for all stakeholders to find workable solutions that balance access to cutting-edge gene therapies and cellular immunotherapies for patients with affordable financing and coverage. Summits like this are essential to making that a reality.
Managing Director, Legislative & Regulatory Policy, Blue Cross Blue Shield Association, 2026 Speaker
Explore the Full Event Guide
- 20+ speakers from leading cell and gene manufacturers, healthcare providers, commercial and government payers, and policy experts
- Network with 80+ like-minded professionals focused on addressing the latest policy and commercialization challenges for cell and gene therapies
- Hear case studies from involvement with the Cell and Gene Therapy Access Model, and the latest on launching a product in 2026
- The only meeting exclusively dedicated to market access, pricing, and reimbursement challenges for cell and gene therapies
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Dive into the only agenda that unpacks real world cell and gene therapy pricing, reimbursement, evidence generation, payer strategy, and policy shifts shaping market viability today.
Partner With Us
Position your solutions at the center of cell and gene therapy market access, payer engagement, and commercialization strategy conversations attended by the field’s leading decisionmakers.
Join Biopharma Experts
Network with the manufacturers, payers, policy leaders, and access strategists defining the future of cell and gene therapy coverage, affordability, and sustainable patient access.